Millennium Management LLC Purchases 2,902,375 Shares of Amicus Therapeutics, Inc. $FOLD

Millennium Management LLC boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 635.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,359,389 shares of the biopharmaceutical company’s stock after purchasing an additional 2,902,375 shares during the quarter. Millennium Management LLC owned about 1.09% of Amicus Therapeutics worth $27,413,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics in the 4th quarter valued at $29,000. PNC Financial Services Group Inc. boosted its stake in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Amicus Therapeutics in the 1st quarter valued at $53,000. GF Fund Management CO. LTD. bought a new stake in Amicus Therapeutics in the 4th quarter valued at $59,000. Finally, GAMMA Investing LLC lifted its position in shares of Amicus Therapeutics by 1,610.8% during the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 7,007 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on FOLD shares. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Wall Street Zen cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 30th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $8.02 on Friday. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65. The company has a market cap of $2.47 billion, a P/E ratio of -66.83 and a beta of 0.55. The business has a fifty day simple moving average of $6.91 and a 200 day simple moving average of $7.02.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.